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Abstract
Hemangioblastomas are rare and benign tumors accounting for less than 2% of all central nervous system (CNS) tumors. The 
vast majority of hemangioblastomas occur sporadically, whereas a small number of cases, especially in younger patients, are 
associated with Von Hippel–Lindau (VHL) syndrome. It is thought that loss of tumor suppressor function of the VHL gene 
results in stabilization of hypoxia-inducible factor alpha with downstream activation of cellular proliferative and angiogenic 
genes that promote tumorigenesis. VHL-related hemangioblastomas predominantly occur in the cerebellum and spine. Lesions 
are often diagnosed on contrast-enhanced craniospinal MRIs, and the diagnosis of VHL occurs through assessment for germline 
VHL mutations. Surgical resection remains the primary treatment modality for symptomatic or worrisome lesions, with excellent 
local control rates and neurological outcomes. Stereotactic radiotherapy can be employed in patients who are deemed high risk 
for surgery, have multiple lesions, or have non-resectable lesions. Given the tendency for development of either new or multiple 
lesions, close radiographic surveillance is often recommended for asymptomatic lesions.
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Introduction
Hemangioblastomas (HB) are rare low-grade vascular tu-
mors within the central nervous system (CNS) identified by 
the World Health Organization (WHO) criteria as Grade I tu-
mors and account for 1–2% of CNS tumors (1). They consist 
of closely packed capillaries within proliferative stromal cells 
which form the main neoplastic component and harbor the 
genetic defect (2). HB can occur as solitary sporadic tumors 
or as multiple familial tumors associated with von Hippel–
Lindau (VHL), an autosomal dominant disorder (3). Some 
of the key clinical and genetic epidemiologic features of VHL 
syndrome are highlighted in Table 1 (4). The overwhelming 
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majority of HB occur sporadically (3). VHL-related HB 
arise from defects associated with loss of tumor suppression 
function of the VHL gene (3, 5–7). Multiple HB can be seen 
in at least 60% of VHL patients (8–12). The most common 
locations for VHL-HB within the CNS include the posterior 
fossa and spinal cord (1). Given the locational CNS predilec-
tion, HB can be a significant source of morbidity and mor-
tality in VHL patients. In fact, the most common cause of 
demise in VHL patients appears to be from posterior fossa 
hemorrhages associated with HB and also renal cell carci-
noma (RCC), which is also part of the syndrome (8, 13, 14). 
Surgical resection of symptomatic or radiographically pro-
gressing lesions can be curative.
Pathogenesis of HB in VHL
VHL is an autosomal dominant syndrome with age-related 
penetrance, characterized with over 300 germ-line mutations 
of the VHL gene on the short arm of chromosome 3p25 (15, 
16). Deletion of a single copy of the VHL gene, also known 
as loss of heterozygosity, can predispose patients to the syn-
drome. Approximately one-third of VHL cases involve dele-
tion mutations, whereas the remaining two-thirds are related 
non-deletion mutations (15, 16). The subsequent loss of the 
tumor suppressive function of VHL secondary to inactiva-
tion of both alleles has been postulated as the basis for the 
development of neoplasms such as HB, pheochromocytomas, 
and RCC in patients with VHL (17, 18). Although the vast 
majority of VHL cases have a familial genetic pattern, the 
syndrome can also manifest de novo without a prior family 
history. In a large series of 181 patients with VHL evaluated 
at the National Institutes of Health (NIH), 41 patients did 
not have a family history diagnosis of VHL suggesting a de 
novo manifestation (19). However, although VHL germline 
mutations might not be apparent when assessed by standard 
techniques such as Southern blot and gene sequencing, fur-
ther analysis of segments of peripheral blood lymphocytes 
using additional molecular techniques might uncover the 
mutation, hence underscoring the significance of genetic mo-
saicism (19). It has, therefore, been postulated that parental 
mosaicism might account for some of the de novo or spo-
radic cases of VHL (19).
The main function of the VHL gene product (pVHL) is 
regulation through ubiquitination of hypoxia-inducible fac-
tor alpha (HIF-α), the major mediator of the cellular re-
sponse to hypoxia (20–22). In the presence of oxygen, the 
proline residues of HIF-α are hydroxylated by prolyl hy-
droxylase enzymes (20, 21, 23). The hydroxylation provides 
a ubiquitination tag on HIF-α for the VHL complex. VHL 
protein forms a VHL complex through interaction of its 
binding domains with elongation factors (elongin C and elon-
gin B), and cullin-2 (20–22). Binding of the beta domain of 
this VHL complex with prolyl-hydroxylated HIF-α results 
in ubiquitination and degradation of HIF-α (24). However, 
prolyl-hydroxylation of HIF-α does not occur in hypoxic con-
ditions (25, 26). As such, the VHL protein complex does not 
recognize and bind to HIF-α. Similarly, defects in VHL pro-
tein complex prevent its regulation and degradation of HIF-
α. Hence, it is postulated that aberrancies in VHL leading to 
stabilization of HIF-α result in downstream up-regulation of 
hypoxia response genes, such as vascular endothelial growth 
factor (VEGF) and platelet-derived growth factor (PDGF), 
that have a role in neoplastic transformation (25, 27, 28).
Although genetic defects in VHL can predispose to HB in 
the craniospinal axis, the genetic mechanisms through which 
HB develop are not fully elucidated. Besides VHL mutations, 
germline allelic variations of several genes including CCND1, 
MMP1, and MMP3 have been implicated in pathogenesis 
of HB (29). Several studies that examined tissue expression 
of EGFR in HB demonstrated universally that there was an 
over-expression of EGFR in HB (30–32). This is not surpris-
ing because EGFR plays a role in cell proliferation and an-
giogenesis. A more recent large study of 44 HB samples using 
droplet digital polymerase chain reaction and high-resolution 
single nucleotide polymorphism (SNR) arrays implicated 
23 candidate in the pathogenesis of HB (33). The candidate 
genes included the following: EGFR, PRDM16, PTPN11, 
Table 1. Epidemiology-related parameters of VHL
VHL degree of incidence 1 in 36,000
VHL point prevalence 1 in 38,000
Age range of diagnosis (years) Infancy to 70
Average age of diagnosis (years) 26–29
Average age for full penetrance of 
VHL
70
Male:female penetrance 1:1
De novo VHL mutations 20%
Familial VHL mutations 80%
Common clinical manifestation
Presenting in 
VHL cases (%)
CNS HB 30–80
Renal cell carcinoma 30–70
Renal cysts 60
Retinal angiomas 15–70
Endolymphatic sac tumors 3–16
Pancreatic cyst 20–70
Pancreatic neuroendocrine tumor 15–56
Pheochromocytoma 16
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HOXD11, HOXD13, FLT3, PTCH, FGFR1, FOXP1, 
GPC3, HOXC13, HOXC11, MKL1, CHEK2, IRF4, GPHN, 
IKZF1, RB1, and HOXA9, and micro RNA, such as hsa-
mir-196a-2. The most common aberrations were deletion of 
CHEK2 and amplifications of EGFR, PTPN11, and PTCH. 
In general, the genes implicated are functionally involved with 
cell proliferation and angiogenesis, which accounts for the 
highly vascular phenotype of HB.
Clinical presentation
Patients with HB can be asymptomatic or symptomatic 
based on the location and mass effects of the tumor (3, 34, 
35). Lesions in the posterior fossa can hemorrhage and cause 
obstructive hydrocephalus and associated symptoms of nau-
sea, headaches, ataxia and profound lethargy. In extreme sit-
uations, brainstem compression with subsequent herniation 
has been reported (36). Moreover, even small hemorrhages in 
brainstem lesions can result in profound neurological symp-
toms. In general, symptomatic lesions were usually associated 
with a large cyst and brain edema (37).
Spinal HB can be asymptomatic, associated with pain, or 
produce myelopathic symptoms of  gait impairment, paral-
ysis, sensory deficits, bowel, and bladder dysfunction. Pain 
often precedes myelopathy (38, 39). Myelopathic symptoms 
are usually related to compression of  long tracts with the 
spinal cord from tumor hemorrhage. Less commonly, pa-
tients can present with spinal subarachnoid hemorrhage 
(39, 40). Leptomeningeal dissemination of  HB is an ex-
tremely rare presentation that has been reported in a handful 
of  cases (41–45).
Radiographic diagnosis of HB
HB represents one of the earliest manifestations of VHL syn-
drome (11). Gadolinium-enhanced magnetic resonance im-
aging (MRI) is the best diagnostic modality for HB because 
its resolution is markedly superior to CT (46, 47). They ap-
pear as homogenously enhancing lesions and are sometimes 
associated with a cystic component. Hemorrhage might be 
present. Tumors can be seen in the brainstem, cerebellum, 
or spinal cord (Figure 1). Spinal cord lesions can exist on 
the pial surface as small enhancing nodules or intramed-
ullary with associated syrinx. Symptomatic spinal HB are 
often associated with syrinx and edema (48). Larger spinal 
HB are more likely associated with flow voids compared to 
smaller HB (48). Patients who are known to be at risk for 
VHL can be screened with MRI of the neural axis. Similarly, 
if  a lesion is noted on brain MRI, then an MRI of the spine 
is recommended.
Alternative diagnostic modalities include contrast- 
enhanced CT scans and angiography (49–51). CT might 
Figure 1. Sagittal MRI of posterior fossa and cervical spine. Left: T1 with gadolinium shows multiple enhancing HB tumors 
involving cerebellum, brainstem, and spinal cord. Right: T2 MRI shows multiple intramedullary cystic lesions consistent with 
VHL hemangioblastoma.
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be employed where there are contraindications to MRI. 
Homogenously enhancing nodules can be seen on the pial 
surface with CT. CT can also assess the extent of cystic com-
pression, hemorrhage, and hydrocephalus in the case of large 
posterior fossa lesions. Angiography can demonstrate the 
classic tumor vascular blush.
Natural history of HB
Several studies have examined the natural history of HB 
as it relates to the development of symptoms and optimal 
timing of interventions (1, 35, 52). Because some HB lesions 
might remain asymptomatic for very long periods of time, 
it is important to avoid unnecessary surgeries in this patient 
population.
Wanebo et al. retrospectively examined 160 consecutive pa-
tients with VHL through correlating clinical history with se-
rial volumetric analysis of tumors on MRI (52). They noted 
a predilection of cystic lesion towards the cerebellum, spi-
nal cord, and brainstem. Compared to the associated tumor 
nodule, the cysts expanded faster and were the basis for neu-
rological symptoms as opposed to the actual tumor. What 
was also noteworthy was the fact that a significant number of 
untreated asymptomatic lesions maintained their status quo 
for many years. From the above study, it appears that cys-
tic lesions should be cautiously observed and considered for 
treatment whenever there is substantial interval expansion 
with risks to vital structures.
In another retrospective study of 158 patients with VHL 
over a 10-year span, Ammerman and colleagues reported 
symptomatic lesions in only 41% of patients over that time 
span (1). The vast majority of lesions remained asymptom-
atic even with radiographic progression. The authors used 
clinical symptoms as opposed to radiographic progression as 
the basis for surgical intervention. They concluded that such 
an approach spared each patient from four additional unnec-
essary procedures over that 10 years time span.
The natural history of HB has been assessed in a pro-
spective format as well. Lonser and colleagues prospectively 
enrolled 225 VHL patients with HB to assess for factors as-
sociated with tumorigenesis and neurological symptoms (53). 
Their assessment of increased tumors burden revealed a pre-
dilection for male sex and partial deletions in VHL gene. In 
addition, younger patients were most likely to develop new 
tumors. Furthermore, rapidly growing tumors were most 
likely encountered in male patients, most likely symptomatic, 
and associated with a cyst. Hence, the above considerations 
should be taken into account in the management of treat-
ment of VHL patients with HB.
Surgical resection of craniospinal HB
Surgery is the preferred treatment modality of HB given the 
low morbidity of surgery. Surgery can relieve compressive 
neurological symptoms and can be curative. Although the 
role of surgery is clear for symptomatic or large lesions, sur-
gery for asymptomatic lesions is debatable (52, 53). Some 
have advocated for treating intramedullary lesions at the 
onset of diagnosis as opposed to the development of neuro-
logical symptoms based on the observation that patients are 
least likely to improve after surgery following neurological 
deterioration (53–55). However, a recent prospective study 
on the natural history of 1921 CNS HB in 225 VHL patients 
found that the vast majority of asymptomatic lesions pro-
gressed in a stepwise fashion whereby neither absolute tumor 
size nor rate of tumor growth was the universal determinant 
of neurological symptoms (35). The authors concluded that 
surgery for HB should only be recommended at the onset of 
neurological symptoms (35).
Surgical resection of HB is similar to resection of any vas-
cular malformation. Because HB are highly vascular lesions, 
the goal of resection entails circumferential dissection along 
the interface between tumor and brain without prematurely 
violating the tumor. Arterial feeders are circumferentially co-
agulated and disconnected resulting in an en-bloc resection 
with risks for intraoperative as well as postoperative hem-
orrhage. A midline myelotomy offers the safest approach 
that minimizes damage to the posterior columns. In some 
instances, preoperative embolization could be considered in 
order to minimize postoperative blood loss (56–58). Because 
spinal lesions are generally intramedullary, neurophysiologic 
monitoring of sensory and motor evoke potentials should 
be incorporated as part of the resection strategy. Similarly, 
lesions in the brainstem might warrant monitoring of the 
above modalities as well as brainstem monitoring.
As previously mentioned, surgical resection of HB can be 
curative with less morbidity at experienced centers. There are 
tumor-related characteristics that can significantly impact 
outcomes. In one study, solid tumor configuration, but not 
tumor size, was noted to be the key determinant of imme-
diate or long-term postoperative outcomes in patients with 
cerebellar HB (59). For instance, in that study patients with 
solid tumors had a propensity for postoperative hematomas 
requiring surgical intervention. In terms of long-term out-
comes, patients with solid tumors had a markedly negative 
outcome compared to those with solid tumors. Because solid 
tumors are very vascular, preoperative embolization could 
minimize the chances of postoperative hematomas in the 
posterior fossa.
Favorable outcomes have been reported for tumors in the 
medulla and spinal cord when the onset of symptoms was 
the main indication for surgical intervention. Parker and col-
leagues (60) reported their experience in 34 patients with HB 
and a mean age of 41. They attained gross total tumor resection 
in approximately 85% of cases. There were no mortalities from 
surgery, and less than 18% of patients experienced worsening 
of symptoms following surgery. In another study of 14 pa-
tients with 15 brainstem HB lesions, Pavesi and colleagues (61) 
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reported that although patients with brainstem lesions were 
more likely to have immediate postoperative deficits, the long-
term outcomes were highly favorable. For instance, following 
surgery, 9 out of 14 patients experienced transient neurolog-
ical deficits. However, at long-term follow-up, at least 10 pa-
tients had performance levels superior to their preoperative 
performance. The role of intraoperative neurophysiological 
monitoring (IONM) in improving outcomes during resection 
of spinal HB has been evaluated and emphasized (62). In a 
series of 24 patients who underwent surgeries for 27 lesions, 
the authors noted a strong correlation between a patholog-
ical IONM findings and an adverse outcome (62). On the 
contrary, patients who had nonpathological IONM findings 
were significantly less likely to have new sensorimotor deficits 
following surgical resection.
Radiotherapy for HB
In situations where patients are not good surgical resection 
candidates or where lesions are not amenable to safe resec-
tion, stereotactic radiation is a favorable option. Radiation 
can also be used to address multiple lesions as well as in the 
setting of tumor recurrence. Although not a curative strategy, 
it can provide reasonable and sustained local tumor control 
(63–68).
Kano and colleagues published one of the largest series 
evaluating the long-term outcomes of stereotactic radiosur-
gery (SRS) in the management of HB consisting of 186 pa-
tients with 517 lesions (64). They reported overall survival 
rates of 94% at 3 years, 90% at 5 years, and 74% at 10 years. 
The associated tumor control rates were 92% at 3 years, 89% 
at 5 years, and 79% at 10 years. Hence, excellent local control 
rates are feasible with SRS.
However, it is worthwhile noting that there appears to be 
differential response to intracranial SRS for sporadic versus 
VHL-related HB. In their assessment of long-term outcomes 
in 57 intracranial HB treated with SRS, Hanakita and col-
leagues reported 5- and 10-year tumor control rates of 67 and 
44%, respectively, for sporadic HB compared to 97 and 83% , 
respectively, for VHL-related HB (67). Besides VHL pathol-
ogy, SRS was much effective for small and solid tumors com-
pared to large and cystic tumors.
SRS is equally effective for spinal HB in terms of halting 
tumor progression and improving neurological symptoms as-
sociated with HB. Pan and colleagues assessed radiographic 
and clinical outcomes in 34 spinal HB tumors (66). Following 
SRS treatment, 94% of the tumors were either stable or re-
gressed with local control rates at 1, 3, and 5 years being 96, 
92, and 92%, respectively. Symptom improvement was asso-
ciated with 81% of treated lesions. Hence, SRS was deemed 
as a safe approach for spinal HB.
A recent systematic review comparison of retrospective data 
of surgical resection versus SRS for spinal HB showed that 
only 2% of tumors treated with SRS actually progressed (69). 
SRS was associated with minimal side effects. The same study 
showed that surgical resection resulted in successful removal 
of tumor with a recurrence rate of approximately 5%. It was 
also evident that at least 96% of patients were either clinically 
stable or improved on long-term follow-up from surgery. It is 
worthwhile noting that no statistical comparisons could be 
done between the surgery and SRS cohort which is a major 
limitation.
Overall, SRS for HB appears to be an effective alternative 
strategy whenever safe surgical resection is not practical. It 
appears to be more effective for VHL patients with HB, small 
tumors, and solid lesions.
Conclusion
Although HB are benign tumors, they can cause significant 
neurological impairment or even mortality following intra-
tumoral hemorrhage or cystic expansion of tumor. Because 
the vast majority of lesions are asymptomatic with very min-
imal growth, observation is reasonable. Factors associated 
with tumor progression and treatment outcomes should be 
considered in the timing of interventions. Lesions that are 
symptomatic or demonstrate worrisome radiographic fea-
tures warrant surgery resection if  safely feasible. Radiosur-
gery remains an acceptable alternative to surgical resection. 
Excellent long-term outcomes can be expected with surgery 
and radiation.
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